)
)
Insmed Investor Relations Material
Latest events
Q3 2024
Insmed
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Insmed Incorporated
Access all reports
Insmed Incorporated is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for patients living with serious and rare diseases. The Company's marketed product ARIKAYCE, or L-Amikacin, is approved in the United States for the treatment of Mycobacterium avium complex lung disease as part of a combination anti-mycobacterial drug regimen for adult patients who are refractory to or intolerant of conventional treatments.
Key slides for Insmed Incorporated
Q4 2023
Insmed Incorporated
Jefferies London Healthcare Conference 2024
Insmed Incorporated
Latest articles
)
Prada: The Story of an Icon
Prada's journey from a small Milan boutique to a global luxury empire, led by Miuccia's innovation and creativity.
5 Dec 2024
)
Hims & Hers: Bridging Gaps in Telehealth
Hims & Hers was founded in 2016 by Andrew Dudum and has grown into a ~$4 billion company in the telehealth industry in less than a decade.
5 Dec 2024
)
Andrew Dudum: Founder and CEO of Hims & Hers
Andrew Dudum is the founder and CEO of Hims & Hers, an innovative telehealth company focused on bridging the gap between consumers and healthcare.
4 Dec 2024
Ticker symbol
INSM
Country
🇺🇸 United States